To stay true to our mission to improve treatment for patients and shape the future of cancer therapy, our research is fully independent. EORTC is a non-profit organisation under Belgian law, with no direct government subsidy. Our revenue comes from grants from institutional, corporate and private donors and fees charged for studies conducted with partners or services to the oncology community (such as running scientific events).
EORTC is grateful to all its supporters, who help ensure therapeutic progress for patients.
Core funding comes from donations collected through independent EORTC foundations: the EORTC Cancer Research Fund (ECRF), Friends of EORTC in the UK and Fondation Française pour la Recherche et le Traitement du Cancer in France. These bodies are supported by public and private donors, including national cancer leagues.
Several public and private foundations provide funding for EORTC operations or projects, including the Belgian national lottery (Loterie Nationale/Nationale Loterij), FOCA, Kom op tegen Kanker, the Dutch KWF Kanker Bestrijding, the Schroeder Foundation, the Melvin Seiden Foundation, Le Fonds Baillet Latour and the Pfizer Foundation (within the framework of the PROBE project).
Partnerships with other research groups
To maximize the impact of research and recruit large numbers of patients in our trials in the shortest possible time, EORTC is taking part in many collaborative clinical trials with other cancer research groups across the globe, which are financed through various sources.
Corporate Social Responsibility programmes
Some corporations support EORTC activities through grants or donations. For example, Walgreens Boots Alliance has an international partnership with EORTC whereby funds raised contribute to the SPECTAcolor Biobank studying advanced colorectal cancer (cancer of the colon or rectum, also known as bowel cancer).
Some EORTC research projects receive grants from the European Commission under the Horizon 2020 programme, the EU Framework Programme for Research and Innovation, and the Innovative Medicines Initiative (IMI).
Funding from industry
Clinical studies evaluating new drugs for potential registration, or testing therapeutic agents, are conducted in partnership with commercial organisations. This funding is subject to EORTC’s strict principles of independence (link to activities/clinical trials/operating principles). Pharmaceutical companies also provide support for EORTC conferences in the form of ‘unrestricted grants’.